Prasad S. Adusumilli, MB, BS

Publications

231

4 grants

PI
Intraperitoneal CAR T-cell therapy for peritoneal mesothelioma
NIH · 2026–2030 · via NIH RePORTER
R01FD008780-01
PI
Tuning KITv CAR T cells for the solid tumor environment
NCI · 2024–2029 · via NIH RePORTER
R01CA292664-03
PI
CD28-KITv CAR T cells with PD-1 dominant negative receptor
NCI · 2024–2029 · via NIH RePORTER
UH3CA290241-03
PI
CD28-KITv CAR T cells with PD-1 dominant negative receptor
NCI · 2024–2026 · via NIH RePORTER
UG3CA290241-02

Completed grants (6)

PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
NCI · 2019–2025 · via NIH RePORTER
R01CA235667-06
MPI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
NCI · 2018–2024 · via NIH RePORTER
R01CA236615-05
PI
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy
NCI · 2017–2020 · via NIH RePORTER
R21CA213139-02
MPI
Full PROJ 1: Preclinical Evaluation, Clinical Trial Preparation and a Prospectiv
NCI · 2008–2018 · via NIH RePORTER
U54CA137788-07
PI
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
NCI · 2012–2014 · via NIH RePORTER
R21CA164585-02
PI
Validation of a risk model for stage I lung adenocarcinoma
NCI · 2012–2014 · via NIH RePORTER
R21CA164568-02